JNJ News & Events

Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration approved Darzalex Faspro in combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. "D-VRd is the only anti-CD38 antibody-based regimen with approved indications across newly diagnosed patients, regardless of transplant eligibility," the company stated.

The Food and Drug Administration announced it has approved daratumumab and hyaluronidase-fihj, or Darzalex Faspro from Janssen Biotech, in combination with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.